Cargando…

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruse, Vibeke, Denys, Hannelore, Van Den Broecke, Rudy, Van Belle, Simon, Cocquyt, Veronique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661078/ https://www.ncbi.nlm.nih.gov/pubmed/23710429 http://dx.doi.org/10.1186/2193-1801-2-202

Ejemplares similares

Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth
por: Lore, Lapeire, et al.
Publicado: (2017)

Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion
por: Van Bockstal, Mieke, et al.
Publicado: (2014)

Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research
por: Vergauwen, Glenn, et al.
Publicado: (2017)

Which Patients Would Most Likely to Benefit: MIGS or MEGS, Which One Is It?
por: Sheheitli, Huda, et al.
Publicado: (2019)

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma
por: Göker, Menekse, et al.
Publicado: (2023)

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?
por: Babaier, Abdulaziz, et al.
Publicado: (2023)

Which Benefits Are Mentioned Most Often in Drug Development Publications?
por: Strüver, Vanessa
Publicado: (2017)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Who benefits most?
por: Van Diermen, L.
Publicado: (2021)

Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?
por: Zhao, Beibo, et al.
Publicado: (2023)

B-Cell Acute Lymphoblastic Leukaemia of the Uterus
por: Vanheule, Eva, et al.
Publicado: (2020)

WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
por: Gamulin, Marija, et al.
Publicado: (2019)

Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?
por: Kovacs, Boldizsar, et al.
Publicado: (2018)

Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
por: Surma, Stanisław, et al.
Publicado: (2022)

Impact of Helicopter Emergency Medical Service in Traumatized Patients: Which Patient Benefits Most?
por: Andruszkow, Hagen, et al.
Publicado: (2016)

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
por: Ntentas, Georgios, et al.
Publicado: (2019)

Primary intestinal type adenocarcinoma of the female genital tract, arisen from a tubulo-villous adenoma: Case report()
por: van Wessel, Steffi, et al.
Publicado: (2013)

Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
por: Vincent, Vakaet, et al.
Publicado: (2022)

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
por: Macedo, Ligia Traldi, et al.
Publicado: (2012)

Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most?
por: van Deutekom, Hanneke W. M., et al.
Publicado: (2015)

Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis
por: Saerens, Michael, et al.
Publicado: (2021)

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis
por: Zhou, Mingyi, et al.
Publicado: (2013)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
por: Klavans, Madison R., et al.
Publicado: (2020)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Which theory has the most holes?
Publicado: (2008)

Which Is the Most Significant Cause of Aging?
por: Liochev, Stefan I.
Publicado: (2015)

Which legal procedure affects business investment most, and which companies are most sensitive? Evidence from microdata()
por: Dejuan-Bitria, Daniel, et al.
Publicado: (2021)

Breast Amyloidosis: A Case Report and Literature Review
por: De Crem, Anne-Sofie, et al.
Publicado: (2022)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
por: Tol, J., et al.
Publicado: (2008)

Do self-management interventions in COPD patients work and which patients benefit most? An individual patient data meta-analysis
por: Jonkman, Nini H, et al.
Publicado: (2016)

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Lima, André Bacellar Costa, et al.
Publicado: (2011)

The Hour at Which Death Most Usually Occurs
Publicado: (1890)

The Hour at Which Death Most Usually Occurs
Publicado: (1890)

Which Health Systems Provide the Most Health?
por: Braithwaite, R. Scott
Publicado: (2020)

Turbinate surgery: which rhinitis are most at risk
por: Gelardi, Matteo, et al.
Publicado: (2022)

Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
por: Sápi, Johanna, et al.
Publicado: (2015)

Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard
por: Livingston, J. A., et al.
Publicado: (2017)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e3rbbfv15lhthqe404drl6vphe